Zobrazeno 1 - 10
of 24
pro vyhledávání: '"V Goswamy"'
Autor:
A. Konno-Yamamoto, V. Goswamy, A. Calatroni, P.J. Gergen, M. Johnson, R.L. Sorkness, L.B. Bacharier, G.T. O'Connor, M. Kattan, C. Visness, J.E. Gern
Publikováno v:
B53. PEDIATRIC ASTHMA BENCH TO BEDSIDE.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Hagop M. Kantarjian, Helen O. Ajufo, Guillermo Garcia-Manero, Jorge E. Cortes, William G. Wierda, Srdan Verstovsek, Marina Konopleva, Michael Andreeff, Rohit V. Goswamy, Tapan M. Kadia, Vinita Popat, Farhad Ravandi, Steven M. Kornblau, Miguel Velasquez, Carlos Blanco, Naveen Pemmaraju, Abhishek Maiti, Sherry Pierce
Publikováno v:
Blood Advances. 4:1690-1699
The value of event-free survival (EFS) as an end point in acute myeloid leukemia (AML) trials has been questioned. We hypothesized that rather than a surrogate for overall survival (OS), improvement in EFS may decrease the use of health care. In this
Autor:
Jennifer Wang, Rohit V. Goswamy, Devaki Shilpa Surasi, Sumit K. Subudhi, Pavlos Msaouel, Paul G. Corn, Tharakeswara K. Bathala, Arlene O. Siefker-Radtke, Jinesh S. Gheeya, Ana Aparicio, Amishi Yogesh Shah, Matthew T. Campbell, Bilal A. Siddiqui, Sangeeta Goswami, Amado J. Zurita, Jianjun Gao, Eric Jonasch, Nizar M. Tannir, Padmanee Sharma
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundImmune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge
Autor:
Rohit V. Goswamy, Daniel J. Tannenbaum, Nathaniel R. Wilson, Fleur M. Aung, Cristhiam Rojas Hernandez
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 60(3)
Background Platelet transfusion refractoriness (PTR) secondary to human leukocyte antigen (HLA) alloimmunization is a challenge in the treatment of hematology-oncologypatients and increases the risk of morbidity and mortality from bleeding events. Gu
Publikováno v:
Bahrain Medical Bulletin. 40:35-37
Publikováno v:
Blood. 136:1-1
Introduction:Sickle cell disease (SCD) is a debilitating chronic genetic disorder that affects approximately 100,000 people in the United States and millions of people worldwide. Chronically ill patients are at risk of developing psychological disord
Autor:
Sunyoung S. Lee, Milind Javle, Timothy A. Yap, Jinesh S. Gheeya, Wei-Lien Wang, Funda Meric-Bernstam, K.R. Mills Shaw, Benjamin Garmezy, Jordi Rodon, Patrick G. Pilie, Rohit V. Goswamy
Publikováno v:
Annals of Oncology. 31:S270
Autor:
Jordi Rodon Ahnert, Funda Meric-Bernstam, Erick Campbell, Vijaykumar Holla, Dong Yang, Keith Kyewalabye, Ecaterina Ileana Dumbrava, Timothy A. Yap, Rohit V. Goswamy, Hung Le, Nora S. Sanchez, Timothy P. Heffernan, Alexander J. Lazar, Khalida Wani, Kenna Rael Shaw, Patrick G. Pilie, Jinesh S. Gheeya, Wei-Lien Wang, Benjamin Garmezy
Publikováno v:
Journal of Clinical Oncology. 38:3629-3629
3629 Background: ATM is frequently mutated in cancer, and defects may serve as a putative predictive biomarker. However, the functional impact of most ATM variants is not well known. In this study, we examined the relationship between ATM variants an
Publikováno v:
Blood. 134:1170-1170
Introduction Platelet transfusion refractoriness (PTR) secondary to human leukocyte antigen (HLA) alloimmunization is a challenge in the treatment of hematology oncology patients and increases the risk of morbidity and mortality from bleeding events.